Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators.
about
Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugsSetipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.Pirinixic acids: flexible fatty acid mimetics with various biological activities.
P2860
Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Novel prostaglandin receptor m ...... I: non-EP receptor modulators.
@en
type
label
Novel prostaglandin receptor m ...... I: non-EP receptor modulators.
@en
prefLabel
Novel prostaglandin receptor m ...... I: non-EP receptor modulators.
@en
P2860
P50
P1476
Novel prostaglandin receptor m ...... I: non-EP receptor modulators.
@en
P2093
Daniel Flesch
P2860
P356
10.1517/13543776.2013.736495
P407
P577
2012-11-14T00:00:00Z